Biomarkers for selinexor
OwnerAndrea Califano, Mariano Javier Alvarez +1inventors
InventorsAndrea Califano, Mariano Javier Alvarez, Yao Shen
Life of this patent
Estimating the term…
Abstract
A method of treating a patient suffering from multiple myeloma, comprising determining a plurality of protein activity values in a subject suffering from multiple myeloma (MM), each protein activity value corresponding to one of a set of proteins in the subject; determining a classification of the subject as a responder or non-responder to a therapy by a compound represented by structural formula (1); and administering a therapeutically effective amount of the compound represented by structural formula (1) or a pharmaceutically acceptable salt thereof.
Claims38
A method of treating a patient suffering from multiple myeloma, comprising:
- determining a plurality of protein activity values in a subject suffering from multiple myeloma (MM), each protein activity value corresponding to one of a set of proteins in the subject;
- determining a classification of the subject as a responder or non-responder to a therapy by a compound represented by structural formula (1);
- and
- administering a therapeutically effective amount of the compound represented by structural formula (1) or a pharmaceutically acceptable salt thereof
- to the subject determined to be responder.
A method of treating a subject suffering from multiple myeloma, comprising:
- administering a therapeutically effective amount of a compound represented by structural formula (1) or a pharmaceutically acceptable salt thereof
- to the subject suffering from multiple myeloma,
- wherein the subject is determined to be a responder to a therapy by the compound represented by structural formula (1) based on a plurality of protein activity values in the subject, each protein activity value corresponding to one of a set of proteins in the subject.
A method of treating a subject suffering from multiple myeloma, comprising:
- selecting the subject suffering from multiple myeloma only if the subject is determined to be a responder to a therapy by a compound represented by structural formula (1) based on a plurality of protein activity values in the subject, each protein activity value corresponding to one of a set of proteins in the subject;
- and
- administering to the selected subject a therapeutically effective amount of the compound represented by structural formula (1) or a pharmaceutically acceptable salt thereof
A method of treating a subject suffering from multiple myeloma, comprising:
- receiving information of a plurality of protein activity values in a subject suffering from multiple myeloma (MM), each protein activity value corresponding to one of a set of proteins in the subject;
- and
- administering to the subject a therapeutically effective amount of a compound represented by structural formula (1) or a pharmaceutically acceptable salt thereof
- only if the subject is determined to be a responder to a therapy by the compound represented by structural formula (1) based on said plurality of protein activity values.
A method of identifying a subject as a responder or a non-responder, comprising:
- determining a plurality of protein activity values in a subject suffering from multiple myeloma (MM), each protein activity value corresponding to one of a set of proteins in the subject;
- providing the plurality of protein activity values to a trained classifier, the trained classifier being trained to differentiate between responders and non-responders to a therapy by a compound represented by structural formula (1);
- and
- obtaining from the classifier a classification of the subject as a responder or non-responder,
A computer program product for identifying responders and non-responders, the computer program product comprising a computer readable storage medium having program instructions embodied therewith, the program instructions executable by a processor to cause the processor to perform a method comprising:
- determining a plurality of protein activity values in a subject suffering from multiple myeloma (MM), each protein activity value corresponding to one of a set of proteins in the subject;
- providing the plurality of protein activity values to a trained classifier, the trained classifier being trained to differentiate between responders and non-responders to a therapy by a compound represented by structural formula (1) or a pharmaceutically acceptable salt thereof
- and
- obtaining from the classifier a classification of the subject as a responder or non-responder.
Dependencies are inferred from the claim text.